In December 2025, Eli Lilly published the first positive Phase 3 readout for retatrutide (LY3437943), the triple-agonist peptide that had, until then, only been validated at Phase 2 scale
We note ORFO (orforglipron) is widely going to be available and accessible at affordable prices and demand will be strong in 2026, Yee wrote
And here is the crucial detail: semaglutide is already doing much of the heavy lifting by naturally reducing her appetite by roughly 24%
What is GLP-1 GLP-1, or glucagon-like peptide-1, is a naturally occurring hormone in the body playing an important role in sugar metabolism
These are appropriate as additional/secondary codes in most encounters
Q4 2026 (earliest): NDA filing with the FDA for the weight-management indication